Vimarsana
Biggest News Aggregation in the World

Page 4 - Nasdaq Prds News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Prds. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Prds Today - Breaking & Trending Today

Analysts Expect Pardes Biosciences, Inc. (NASDAQ:PRDS) to Announce -$0.39 Earnings Per Share - Vimarsana News

Analysts Expect Pardes Biosciences, Inc. (NASDAQ:PRDS) to Announce -$0.39 Earnings Per Share

Equities research analysts predict that Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) will announce earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Pardes Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.38). The company […]

-$0.25 EPS Expected for Pardes Biosciences, Inc. (NASDAQ:PRDS) This Quarter - Vimarsana News

-$0.25 EPS Expected for Pardes Biosciences, Inc. (NASDAQ:PRDS) This Quarter

Wall Street analysts predict that Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) will post earnings per share of ($0.25) for the current quarter, Zacks reports. Zero analysts have made estimates for Pardes Biosciences’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.27). The company is expected to issue its next earnings report […]

FY2023 EPS Estimates for Pardes Biosciences Inc Decreased by Analyst (NASDAQ:PRDS) - Vimarsana News

FY2023 EPS Estimates for Pardes Biosciences Inc Decreased by Analyst (NASDAQ:PRDS)

Pardes Biosciences Inc (NASDAQ:PRDS – Get Rating) – Equities researchers at SVB Leerink lowered their FY2023 EPS estimates for Pardes Biosciences in a report issued on Wednesday, March 30th. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings per share of $7.00 for the year, down from their prior estimate of […]

Pardes Biosciences Appoints Thomas G. Wiggans to CEO and - Vimarsana News

Pardes Biosciences Appoints Thomas G. Wiggans to CEO and

Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple...